Primary Immunodeficiency (PID)

ASCIA has significantly expanded its range of information for health professionals and patients on Primary Immunodeficiency (PID) since 2014, including the ASCIA Transplantation and PID (TAPID) Project, development of  resources to support the use of subcutaneous immunoglobulin (SCIg) and a dedicated webpage  

TAPID 2018 Meeting

Saturday 5 to Sunday 6 May 2018

Larwill Hotel, Melbourne Australia

docxTAPID2018_meeting_application_form64.33 KB 

pdfTAPID2018_meeting_program70.44 KB


The ASCIA TAPID (Transplantation And PID) project is an important and ongoing collaboration between clinical immunologists, transplant physicians and international PID experts, facilitated by ASCIA.

TAPID meetings enable complex PID and transplantation cases to be discussed in a confidential expert forum.

Since the first TAPID face to face meeting was held in February 2014, the TAPID project membership has increased 5 fold, from 12 to more than 60 members and teleconferences are now held each month.

A TAPID face to face meeting was held in Melbourne in 2017 (20-21 May) and the 2018 meeting will also be held in Melbourne in May (5-6). At the May 2018 ASCIA TAPID meeting, as well as complex PID transplantation cases being presented by up to 40 delegates, a draft ASCIA TAPID publication will also be discussedThe main objective of the TAPID project is to have regular collaborations and discussions between immunologists and  transplant physicians in major centres that transplant patients with PIDs in Australasia.

At the ASCIA PID (APID) Consultants Meeting in May 2013 the concept of the TAPID (transplantation and PID) project was initiated. Since then:

  • TAPID face to face meetings with immunologists and transplant physicians have been held in February 2014 and May 2017.
  • TAPID teleconferences have been held (almost monthly) since mid 2014.

This project has been supported by an unrestricted educational grant from CSL Behring.

ASCIA Immunodeficiency (ID) Register

The objectives of this project are to:

  • Collect data on all patients with primary immune deficiency diseases in Australia and New Zealand.
  • Enhance research, therapies and advocacy for primary and secondary immune deficiencies.

This project is supported by unrestricted educational grants from CSL Behring and Octapharma.

The estimated completion date for this project is mid 2018.


Updated May 2018

Mod ASCIA Member
Donate to AIFA
go to NAS website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.


This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information.Verify here.